<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus is associated with several human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>To examine the effect of Epstein-Barr virus nuclear antigen 1 (EBNA-1) in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, we transfected the gene into the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> cell line L428 </plain></SENT>
<SENT sid="2" pm="."><plain>EBNA-1 expression was associated with significantly enhanced CD25 expression (interleukin 2 [IL-2]-receptor alpha chain) in transient and stably transfected L428 cells but did not affect the expression of IL-2 receptor beta and gamma chains </plain></SENT>
<SENT sid="3" pm="."><plain>There was no up-regulation of the B-cell activation molecules CD23, CD30, CD39, CD40, CD44, CD71, and CD54 (intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1) or enhanced production of IL-6, IL-10, lymphotoxin alpha, and the soluble form of CD25 </plain></SENT>
<SENT sid="4" pm="."><plain>Stable EBNA-1-expressing L428 cells were nontumorigenic in <z:mp ids='MP_0002536'>SCID</z:mp> mice but showed enhanced <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development in nonobese diabetic-<z:mp ids='MP_0002536'>SCID</z:mp> mice compared to mock-transfected cells </plain></SENT>
</text></document>